Interleukin-6 blocking agents for treating COVID-19: a living systematic review-Reference-Cited by-同舟云学术

Interleukin-6 blocking agents for treating COVID-19: a living systematic review

Published:2021-03-18 Issue:3 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ghosn Lina¹²³,Chaimani Anna³,Evrenoglou Theodoros³,Davidson Mauricia¹²³,Graña Carolina¹²³,Schmucker Christine⁴⁵,Bollig Claudia⁴⁵,Henschke Nicholas⁶,Sguassero Yanina⁶,Nejstgaard Camilla Hansen⁷⁸,Menon Sonia¹²³,Nguyen Thu Van³,Ferrand Gabriel¹²³,Kapp Philipp¹²³,Riveros Carolina¹²³,Ávila Camila⁹,Devane Declan¹⁰¹¹,Meerpohl Joerg J⁴⁵,Rada Gabriel⁹¹²,Hróbjartsson Asbjørn⁷⁸,Grasselli Giacomo¹³¹⁴¹⁵,Tovey David¹,Ravaud Philippe¹²³,Boutron Isabelle¹²³

Affiliation:

1. Cochrane France; Paris France

2. Centre d'Épidémiologie Clinique, AP-HP (Assistance Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu; Paris France

3. Université de Paris, Centre of Research in Epidemiology and Statistics (CRESS), INSERM, F-75004; Paris France

4. Cochrane Germany; Cochrane Germany Foundation; Freiburg Germany

5. Institute for Evidence in Medicine (for Cochrane Germany Foundation); Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany

6. Cochrane Response; Cochrane; London UK

7. Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark; Department of Clinical Research, University of Southern Denmark; Odense Denmark

8. Open Patient data Explorative Network (OPEN); Odense University Hospital; Odense Denmark

9. Epistemonikos Foundation; Santiago Chile

10. HRB-Trials Methodology Research Network; National University of Ireland Galway; Galway Ireland

11. Evidence Synthesis Ireland and Cochrane Ireland; Galway Ireland

12. UC Evidence Center, Cochrane Chile Associated Center; Pontificia Universidad Católica de Chile; Santiago Chile

13. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; University of Milan; Milan Italy

14. Department of Anesthesia, Intensive Care and Emergency; Ospedale Maggiore Policlinico, University of Milan; Milan Italy

15. Department of Pathophysiology and Transplantation; Ospedale Maggiore Policlinico, University of Milan; Milan Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference148 articles.

1. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19;Gordon;New England Journal of Medicine,2021

2. Gordon AC Mouncey PR Al-Beidh F Rowan KM Nichol AD Arabi YM The REMAP-CAP Investigators Interleukin-6 receptor antagonists in critically ill patients with Covid-19 - preliminary report medRxiv [Preprint] 2021 10.1101/2021.01.07.21249390

3. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP) clinicaltrials.gov/ct2/show/NCT02735707 10.1101/2021.01.07.21249390

4. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized clinical trial;Hermine;JAMA Internal Medicine,2021

5. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC) clinicaltrials.gov/ct2/show/NCT04331808

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Normalization of IL-6 levels is associated with survival in critically ill patients with COVID-19;Journal of Critical Care;2024-12

2. Pharmacological validation of a novel exopolysaccharide from Streptomyces sp. 139 to effectively inhibit cytokine storms;Heliyon;2024-07

3. Targeting IL-6 trans-signalling by sgp130Fc attenuates severity in SARS-CoV-2 -infected mice and reduces endotheliopathy;eBioMedicine;2024-05

4. Intensivmedizinische Therapie von COVID-19;Pneumologie;2024-05

5. Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19;Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice;2024-04-19